SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 14, 2000
----------------
Generex Biotechnology Corporation
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-25169 82-049021
---------------------------- ----------- --------------------
(State or other jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
33 Harbor Square, Suite 202, Toronto, Ontario Canada M5J 2G2
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 416/364-2551
----------------------------
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
Item 5. Other Events
J. Michael Rosen has been elected a director of Generex Biotechnology
Corporation to fill a vacancy on the Board created by the resignation of Iain
Brown, Sr., who resigned from the Board of Directors for personal reasons on
June 30th of this year.
Mr. Rosen, age 49, has been a principal in a number of related travel
management and hotel marketing businesses specializing in serving the casino
industry since 1978. The principal companies in this group, all of which are
headquartered in Willowdale, Ontario, are Uniworld Travel & Tours, Inc., Nevada
Vacations, Inc., Casino Vacations, Inc. and Casino Tours, Inc. Mr. Rosen
presently serves as the President or a Vice President, and the Chief Financial
Officer, of each of these companies.
Prior to 1978, Mr. Rosen was engaged in the private practice of accounting
in Toronto, Ontario, and Miami, Florida.
Mr. Rosen has also been appointed to the Audit Committee of the Board of
Directors replacing Mr. Brown on that Committee.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENEREX BIOTECHNOLOGY CORPORATION
Dated: August 22, 2000 By: /s/ E. Mark Perri
--------------- ------------------------------------
E. Mark Perri, Chairman and CFO
